Physician profile
Nancy Wallace
NPI 1245996628
$10,450.89
in general payments reported to CMS, 2019-2025
45 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,510 · 2023: $2,470 · 2024: $4,044 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,856 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,856.28 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.59 | 2022-2025 | |
| Ucb, INC. | $729.74 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Lilly USA, LLC | $632.01 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $629.36 | 2023-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $515.37 | 2023-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $426.83 | 2022-2025 | Rexulti, Jynarque, Nuedexta |
| Argenx US, INC. | $416.92 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals Lp | $411.73 | 2022-2023 | Farxiga, Breztri |
| Pfizer INC. | $403.14 | 2023-2025 | |
| Novo Nordisk INC | $402.61 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $382.79 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $382.27 | 2022 | |
| Eisai INC. | $351.87 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $334.89 | 2023-2025 | Rytary, Crexont, Lyvispah |
| Sk Life Science, INC. | $262.17 | 2023-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $253.20 | 2022-2023 | Myrbetriq |
| Catalyst Pharmaceuticals, INC. | $251.87 | 2023-2025 | Fycompa |
| Merck Sharp & Dohme LLC | $243.50 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Lundbeck LLC | $227.21 | 2023-2025 | Vyepti |
| Emd Serono, INC. | $223.41 | 2023-2025 | Mavenclad |
| Glaxosmithkline, LLC. | $217.60 | 2022-2023 | Trelegy Ellipta, Shingrix, Boostrix |
| Neurocrine Biosciences, INC. | $199.63 | 2023-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $149.01 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.95 | 2022-2023 | |
| Kyowa Kirin, INC. | $131.96 | 2023-2025 | Nourianz |
| Neurelis, INC. | $111.84 | 2024-2025 | Valtoco |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.39 | 2022-2023 | Xifaxan |
| Abbott Laboratories | $102.00 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.89 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.29 | 2022-2025 | Hyqvia |
| Biogen, INC. | $75.06 | 2023-2024 | Vumerity, Tysabri, Avonex |
| Celgene Corporation | $64.18 | 2024-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $60.66 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $59.81 | 2022-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $48.10 | 2022 | |
| Seqirus USA INC | $46.10 | 2022 | |
| Exact Sciences Corporation | $45.34 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $44.18 | 2023 | Prolia, Evenity |
| Amarin Pharma, INC. | $42.09 | 2022-2023 | |
| Merz Pharmaceuticals, LLC | $39.43 | 2025 | Ampyra, Inbrija |
| Esperion Therapeutics, INC. | $19.28 | 2022 | |
| Tanabe Pharma America, INC. | $17.91 | 2024 | |
| Sanofi Pasteur INC. | $16.50 | 2022 | |
| Dexcom, INC. | $16.12 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.